[ 8 ] Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangi ogenesis in multiple myeloma via direct and indirect effects on endothelia1 cells[J]. Cancer Ras, 2006, 66(1): 184-191.
[2]
[ 9 ] National Comprehensive Cancer Net work (NCCN). NCCN clinical practice guidelines in oncology TM multiple myeloma (V.3.2008).http//www. nccn.org/peofessionals/physician_gle/PDF/myeloma.pdf.
[3]
National Comprehensive Cancer Net work(NCCN). NCCN clinical practice guidelines in oncology multiple myeloma (V.1.2011). http://www.nccn.org/peofessionals/physician_gle/PDF/myeloma.pdf.
[4]
Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma[J]. Br J Haematol, 2005, 129(6): 776-783.
[5]
Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase Ⅱ study[J]. Haematologica, 2006, 91(11): 1498-1505.
[ 4 ] Kenneth CA, Melissa A, William B, et al. NCCN clinical practice guidelines in oncology multiple myeloma version I[S]. 2011: 17.
[10]
[ 5 ] Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase Ⅱ clinical trial[J]. Leukemia, 2009, 23(7): 1337-1341.
[11]
[ 6 ] Hideshima T, Miltiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341[J]. Blood, 2003, 101(4): 1530-1534.
[12]
[ 7 ] Jullig M, Zhang WV, Ferreira A, et al. MG132 induced apoptosis is associated with P53-independent induction of pro-apoptotic NOXA and transcriptional activity of beta-catenin [J]. Apoptosis, 2006, 11(4): 627-641.
[13]
Harousseau JL , Attal M , Avet-Loiseau H , et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase Ⅲ trial[J]. J Clin Oncol, 2010, 28(30): 4621-4629.
[14]
Corso A , Barbarano L , Mangiacavalli S , et al. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma[J]. Leuk Lymphoma, 2010, 51(2): 236-242.
[15]
Cavo M, Tacchetti P, Patriarca F, et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma[J]. Blood, 2008, 112(11): 65.
[16]
Sonneveld P, van der Holt B, Schmidt-Wolf IGH, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase Ⅲ trial comparing bortezomib, adriamycine, dexamethasone (pad) vs vad as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM)[J]. ASH Annual Meeting Abstracts, 2008, 112(11): 653.
[17]
Rajkumar SV, Hayman SR,Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma[J]. Blood, 2005, 106(13): 4050-4053.
[18]
Richardson P, Lonial S, Jakubowiak A, et al. Lenalidomide, bortezomib,and dexamethasone in patients with newly diagnosed multiple myeloma:encouraging effcacy in high risk Groups with updated results of a phaseⅠ/Ⅱ study[J]. ASH Annual Meeting Abstracts, 2008,112(11): 92.
[19]
Corso A , Barbarano L , Mangiacavalli S , et al. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma [J]. Leuk Lymphoma, 2010, 51(2): 236-242.
Chari A, Mazumder M, Jagannath S. Proteasome inhibition and its therapeutic potential in multiple myeloma[J]. Biologics: Targets & Therapy, 2010, 4(10): 273-287.
[22]
Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase Ⅲ VISTA trial[J]. J Clin Oncol, 2010, 28(13): 2259-2266.
[23]
Palumbo A, Bringhen S, Rossi D, et al. A prospective, randomized, phase Ⅲ study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients[J]. ASH Annual Meeting Abstracts, 2008, 112(11): 652.
[24]
Rotta M, Storer BE, Sahebi F, et al. Long-term outcomeof patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting[J]. Blood, 2009, 113(14): 3383-3391.
[25]
Mandelli F, Avvisati G, Amadori S, et al. Maintenance treatment with recombinant interferon alfa-2b inpatients with multiple myeloma responding to conventional induction chemotherapy[J]. N Engl J Med,1990, 322(10): 1430-1434.
[26]
Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients[J]. Blood, 2002, 99(9): 3163-3168.
[27]
Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure[J]. J Clin Oncol, 2009, 27(11): 1788-1793.
[28]
Attal M, Harousseau JL, Leyvraz S, et al. Maintenanc therapy with thalidomide improves survival in patients with multiple myeloma[J]. Blood, 2006, 108(10): 3289-3294.
[29]
Dispenzieri A , Jacobus S , Vesole DH , et al. Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial[J]. Leukemia , 2010, 24(8): 1406-1411.
[30]
Benevolo G, Larocca A, Gentile M, et al. The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens[J]. Cancer, 2010, 117(9):1884-1890.
[31]
Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial[J]. J Clin Oncol, 2010, 28(34): 5101-5109.
[32]
Uy GL, Goyal SD, Fisher NM, et al. Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase Ⅱ study[J]. Bone Marrow Transplant, 2009, 43(10): 793-800.
[33]
Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma[J]. N Engl J Med, 2003, 348(26): 2609-2617.
[34]
Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or highdose dexamethasone for relapsed multiple myeloma[J]. N Engl J Med, 2005, 352(24): 2487-2498.
[35]
Giuliani N, Morandi F, Tagliaferri S, et al. The proteasome inhibitor bort e zomib affects osteoblast differentiation in vitro and in vivo i n multiple myeloma patients[J]. Blood, 2007, 110(1): 334-338.
[36]
Terpos E, Sezer O, Croucher P, et al. Myeloma bone disease and proteasome inhibition therapies[J]. Blood, 2007, 110(4): 1098-1104.
[37]
Pineda-Roman M , Zangari M , van Rhee F , et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia[J]. 2008, 22(7): 1419-1427.
[38]
Palumbo A , Gay F , Bringhen S , Falcone A , et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma[J]. Ann Oncol, 2008, 19(6): 1160-1165.
[39]
Palumbo A , Ambrosini MT , Benevolo G , et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma[J]. Blood, 2007, 109(7): 2767-2772.
[40]
Richardson P, Jagannath S, Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phaseⅡ study[J]. ASH Annual Meeting Abstracts, 2008, 112(11): 1742.
[41]
Roussou M, Kastritis E, Migkou M, et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens[J]. Leuk Lymphoma, 2008, 49(5): 890-895. [42] Ludwig H, Drach J, Graf H, et al. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma[J]. Haematologica, 2007, 92(10): 1411-1414.
[42]
Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failu re: a multicenter retrospective study[J]. Blood, 2007, 109(6): 2604-2606. [44] Ludwig H , Adam Z , Hajek R , et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phaseⅡ study[J]. J Clin Oncol , 2010, 28(30): 4635-4641.
[43]
Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma[J]. Blood, 2005, 106(12): 3777-3784.
[44]
Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins[J]. J Cell Biol, 1998, 143(7): 1883-1898.
[45]
Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat[J]. Exp Neurol, 2007, 204(1): 317-325.
[46]
Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility f peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib[J]. J Clin Oncol, 2006, 24(19): 3113-3120.
[47]
Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase Ⅲ APEX trial in relapsed multiple myeloma: impact of adose-modifcationguideline[J]. Br J Haematol, 2009, 144(6): 895-903.
[48]
Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature[J]. Blood, 2008, 112(5): 1593-1599.
